The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for JITC, an outlet devoted to and created by today's leaders in the field.
Read the Journal for ImmunoTherapy of Cancer (JITC)
Pedro J. Romero, MD, JITC Editor-in-Chief, welcomes applications from interested individuals who would like to take advantage of the many benefits of serving as a JITC manuscript reviewer. Benefits include:
JITC launched two new sections in 2020 and is now collecting submissions for peer review. Read more about these sections, "Immune Cell Therapies and Immune Cell Engineering" and "Oncolytic and Local Immunotherapy," and submit today!
The Journal for ImmunoTherapy of Cancer (JITC) increased its impact factor to 10.252 in 2020. JITC’s Impact Factor makes JITC the highest ranked fully open access immunology journal and places it in the top 7% percent of all journals published in the categories of oncology and immunology.Published in the annual Journal Citation Reports (JCR), the latest JITC impact factor is a calculation determined on the number of 2019 citations accumulated for JITC manuscripts published in 2017 and 2018. Other valuable journal metrics for JITC may be found on the journal website.
As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 50 percent discount on processing fees for all JITC articles submitted and accepted in 2021.
For questions regarding the discount that would be verified and applied upon post-review acceptance, please contact JITCEditor@sitcancer.org or (414) 271-2456.
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
Modulation and depletion strategies of regulatory T cells (Tregs) constitute valid approaches in antitumor immunotherapy but suffer from severe adverse effects due to their lack of selectivity for the tumor-infiltrating (ti-)Treg population, indicating the need for a ti-Treg specific biomarker.
The advent of immune checkpoint therapy has been a tremendous advance in cancer treatment. However, the responses are still insufficient in patients with soft tissue sarcoma (STS). We aimed to identify rational combinations to increase the response to immune checkpoint therapy and improve survival.
If you are a PhD or PostDoc researching Cancer Immunotherapies, submit your abstract for a chance to speak at our Cancer Immunotherapy meeting on the 29th of April and receive a prize of $250. Confirmed Keynote speakers are Dr John Maher from Kings ...
Pancreas and Related Cancers - Virtual Meeting June 11, 2021
Presented by the Jefferson Pancreas, Biliary, and Related Cancer Center, this conference is specifically designed for health care professionals ...
Dear colleagues I am a second year PhD student and I am pursuing a preclincal study on anti-PD-L1 and anti-PD1 antibodies. I want to start by writing a review article on the topic. If any one is interested to join me!! we can do some brain storming ...
Hi all, I wanted to share with the community an abstract call that could be a nice opportunity to submit the interesting results from aggregated datasets that accumulate in the immunotherapy field. Best regards, Jahan https://www.frontiersin.org/research-topics/19599/re-using-cytometry-datasets-in-immunology-old-wine-into-new-wineskins ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org